New cGMP fermentation facility in the UK set to meet growing demand for drug substance production, supporting biopharma ...

The interim phase 2 trial results show a good immune response in participants and the therapy is well tolerated to date.

The Series D financing will support the clinical development of two ADCs.

The FDA had put a clinical hold on Novavax’s COVID-19-influenza combo vaccine after an adverse event in a patient.

Emraclidine was expected to be a competitor to Bristol Myers Squibb’s recently approved Cobenfy, but trial results put its ...

The Simponi biosimilar, AVT05, has shown positive top-line results in patients with moderate to severe rheumatoid arthritis.

The U.S. company Aditum Bio and Chinese company Leads Biolabs today announced that they have founded Oblenio Bio, a new ...

The Dutch biotech Synaffix and the Swiss company BigHat Biosciences announced yesterday that they have entered into a ...

The US biopharma will discontinue development of the Exondys 51 (eteplirsen) follow up treatment to focus on other treatment ...

At CPHI Milan 2024, Abzena showcased its latest innovations in cell line development and ADC manufacturing, featuring the ...

A new case study released by AllazoHealth reveals that a leading rare disease pharmaceutical company achieved a 10.4% ...

The US biopharma will discontinue development of the Exondys 51 (eteplirsen) follow up treatment to focus on other treatment candidates.